1
|
Held PK, Lasarev M, Zhang X, Wiberley-Bradford AE, Campbell K, Horner V, Shao X, Benoy M, Dodge AM, Peterson AL. Familial Hypercholesterolemia Biomarker Distribution in Dried Blood Spots. J Pediatr 2023; 259:113469. [PMID: 37182660 PMCID: PMC10524346 DOI: 10.1016/j.jpeds.2023.113469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 04/05/2023] [Accepted: 04/21/2023] [Indexed: 05/16/2023]
Abstract
OBJECTIVE To evaluate distribution profiles of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apoB) as candidate markers of familial hypercholesterolemia in newborns, taking into consideration potential confounding factors, such as gestational age, birth weight, sex, and race. STUDY DESIGN TC, LDL-C, and apoB were measured from 10 000 residual deidentified newborn dried blood spot cards. Concentrations for each biomarker were reported as multiples of the median, with emphasis on describing the 99th percentile values based on birth weight, gestational age, sex, and race. Seasonal variation of biomarkers was also explored. RESULTS LDL-C and apoB had distribution curves with tails showing extreme elevation, whereas the distribution of TC was less elevated and had the smallest range. Neonates born at early gestational age and low birth weight had significantly greater 99th percentile of multiples of the median values for apoB but not TC or LDL-C. Differences in biomarker concentration based on sex and race were minimal. All biomarkers showed greatest concentrations in the winter as compared with summer months. CONCLUSIONS LDL-C and apoB had distribution curves supporting candidacy for neonatal familial hypercholesterolemia screening. Future studies are needed to correlate newborn screening results with molecular testing to validate these 2 biomarkers, along with measured cholesterol levels later in childhood.
Collapse
Affiliation(s)
- Patrice K Held
- Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR; Oregon State Public Health Laboratory, Oregon Health Authority, Hillsboro, OR
| | - Michael Lasarev
- Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - Xiao Zhang
- Division of Pediatric Cardiology, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - Amy E Wiberley-Bradford
- Wisconsin State Laboratory of Hygiene, University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - Kristin Campbell
- Wisconsin State Laboratory of Hygiene, University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - Vanessa Horner
- Wisconsin State Laboratory of Hygiene, University of Wisconsin School of Medicine and Public Health, Madison, WI; Department of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - Xiangqiang Shao
- Division of Pediatric Cardiology, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI; Wisconsin State Laboratory of Hygiene, University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - Megan Benoy
- Pediatric Specialty Clinics, University of Wisconsin Hospital and Clinics, Madison, WI
| | - Ann M Dodge
- Division of Pediatric Cardiology, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - Amy L Peterson
- Division of Pediatric Cardiology, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI.
| |
Collapse
|
2
|
Kyriakopoulos C, Taleb I, Wever-Pinzon O, Selzman C, Bonios M, Dranow E, Wever-Pinzon J, Yin M, Tseliou E, Stehlik J, Alharethi R, Kfoury A, Hanff T, Fang J, Koliopoulou A, Sideris K, Krauspe E, Nelson M, Elmer A, Singh R, Psotka M, Birks E, Slaughter M, Koenig S, Kyvernitakis A, Hoffman K, Guglin M, Kotter J, Campbell K, Silvestry S, Vidic A, Raval N, Mehra M, Cowger J, Kanwar M, Shah P, Drakos S. Multicenter Development and Validation of a Machine Learning Model to Predict Myocardial Recovery During LVAD Support: The UCAR Score. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
3
|
Porteous M, Lanthier M, Tavakoli P, Boafo A, Campbell K, De Koninck J, Robillard R. Correlations between sleep architecture and emotional inhibition processing during a suicidal crisis: Preliminary findings in hospitalized adolescents. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
4
|
Campbell K, Afseth J, Dunham M. CN32 Cancer nurses' experiences and perceptions of potential occupational exposure to cytotoxic drugs: Systematic review utilising framework analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Kirkpatrick S, Campbell K. CN59 A scoping review to establish the utility of patient reported outcome measures in blood cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
6
|
Kimble M, Allers S, Campbell K, Chen C, Jackson LM, King BL, Silverbrand S, York G, Beard K. medna-metadata: an open-source data management system for tracking environmental DNA samples and metadata. Bioinformatics 2022; 38:4589-4597. [PMID: 35960154 PMCID: PMC9524998 DOI: 10.1093/bioinformatics/btac556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Revised: 07/23/2022] [Accepted: 08/09/2022] [Indexed: 12/24/2022] Open
Abstract
MOTIVATION Environmental DNA (eDNA), as a rapidly expanding research field, stands to benefit from shared resources including sampling protocols, study designs, discovered sequences, and taxonomic assignments to sequences. High-quality community shareable eDNA resources rely heavily on comprehensive metadata documentation that captures the complex workflows covering field sampling, molecular biology lab work, and bioinformatic analyses. There are limited sources that provide documentation of database development on comprehensive metadata for eDNA and these workflows and no open-source software. RESULTS We present medna-metadata, an open-source, modular system that aligns with Findable, Accessible, Interoperable, and Reusable guiding principles that support scholarly data reuse and the database and application development of a standardized metadata collection structure that encapsulates critical aspects of field data collection, wet lab processing, and bioinformatic analysis. Medna-metadata is showcased with metabarcoding data from the Gulf of Maine (Polinski et al., 2019). AVAILABILITY AND IMPLEMENTATION The source code of the medna-metadata web application is hosted on GitHub (https://github.com/Maine-eDNA/medna-metadata). Medna-metadata is a docker-compose installable package. Documentation can be found at https://medna-metadata.readthedocs.io/en/latest/?badge=latest. The application is implemented in Python, PostgreSQL and PostGIS, RabbitMQ, and NGINX, with all major browsers supported. A demo can be found at https://demo.metadata.maine-edna.org/. SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
Collapse
Affiliation(s)
- M Kimble
- To whom correspondence should be addressed.
| | - S Allers
- Department of Molecular and Biomedical Sciences, University of Maine, Orono, ME 04469, USA
| | - K Campbell
- School of Computing and Information Science, University of Maine, Orono, ME 04469, USA
| | - C Chen
- School of Computing and Information Science, University of Maine, Orono, ME 04469, USA
| | - L M Jackson
- Advanced Research Computing, Security and Information Management, University of Maine, Orono, ME 04469, USA,Maine EPSCoR, University of Maine, Orono, ME 04469, USA
| | - B L King
- Department of Molecular and Biomedical Sciences, University of Maine, Orono, ME 04469, USA
| | - S Silverbrand
- School of Marine Sciences, University of Maine, Orono, ME 04469, USA
| | - G York
- Environmental DNA Laboratory, Coordinated Operating Research Entities, University of Maine, Orono, ME 04469, USA
| | - K Beard
- School of Computing and Information Science, University of Maine, Orono, ME 04469, USA
| |
Collapse
|
7
|
Zhang Y, Clarke A, Regan KH, Campbell K, Donaldson S, Crowe J, Rossi AG, Hill AT. Isolated IgG2 deficiency is an independent risk factor for exacerbations in bronchiectasis. QJM 2022; 115:292-297. [PMID: 33970283 PMCID: PMC9086763 DOI: 10.1093/qjmed/hcab129] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Revised: 04/26/2021] [Accepted: 05/06/2021] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Immunoglobulin G (IgG) subclass 2 deficiency is the most frequent IgG subclass deficiency identified in patients with bronchiectasis, but its clinical significance is not known. AIM To analyse if bronchiectasis patients with isolated IgG2 deficiency at risk of recurrent exacerbations and/or hospitalization? Do patients with IgG2 deficiency have worse disease progression? DESIGN AND METHODS This is a retrospective study (2015-20) exploring independent risk factors for recurrent exacerbations (3 or more per year) and/or hospitalization with bronchiectasis exacerbations using multivariable models using binary logistic regression. There was no patient with IgG deficiency, IgG 1, 3 or 4 deficiency, or IgA or IgM deficiency included. In this model, the authors included: serum IgG2 level; lung function; body mass index; MRC breathlessness scale; age; sex; number of bronchiectatic lobes; bacterial colonization; comorbidities; and the use of long-term immunosuppressant drugs or antibiotics for more than 28 days. Analysing 2-year longitudinal data, one-way ANOVA and Mann-Whitney U-test were used to compare bronchiectasis severity between patients with different IgG2 levels. RESULTS Serum IgG2 levels (<2.68 g/l, 2.68-3.53 g/l and 3.54-4.45 g/l); hospital admission in the preceding 2 years; bacterial colonization with potentially pathogenic organisms and asthma were independent predictors for three or more bronchiectasis exacerbations. Those with low IgG2 levels (<2.68 g/l and 2.68-3.53 g/l), had worsening progression of their bronchiectasis, using the Bronchiectasis Severity Index, over 1 year compared with those who were IgG2 replete (>4.45 g/l) (P = 0.003, 0.013). CONCLUSION Reduced IgG2 levels were an independent predictor for bronchiectasis exacerbations and have increased disease progression.
Collapse
Affiliation(s)
- Y Zhang
- The Centre for Inflammation Research at the University of Edinburgh, Queen’s Medical Research Institute, Edinburgh BioQuarter, Edinburgh EH16 4TJ, UK
| | - A Clarke
- The Centre for Inflammation Research at the University of Edinburgh, Queen’s Medical Research Institute, Edinburgh BioQuarter, Edinburgh EH16 4TJ, UK
- Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK
| | - K H Regan
- The Centre for Inflammation Research at the University of Edinburgh, Queen’s Medical Research Institute, Edinburgh BioQuarter, Edinburgh EH16 4TJ, UK
- Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK
| | - K Campbell
- Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK
| | - S Donaldson
- The Centre for Inflammation Research at the University of Edinburgh, Queen’s Medical Research Institute, Edinburgh BioQuarter, Edinburgh EH16 4TJ, UK
- Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK
| | - J Crowe
- Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK
| | - A G Rossi
- The Centre for Inflammation Research at the University of Edinburgh, Queen’s Medical Research Institute, Edinburgh BioQuarter, Edinburgh EH16 4TJ, UK
| | - A T Hill
- Address correspondence to Prof A.T. Hill, Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK.
| |
Collapse
|
8
|
Trinh L, Sabiston CM, Alibhai SMH, Jones JM, Arbour-Nicitopoulos KP, Mina DS, Campbell K, Faulkner GE. A distance-based, randomized controlled trial for reducing sedentary behavior among prostate cancer survivors: a study protocol. BMC Public Health 2022; 22:855. [PMID: 35484523 PMCID: PMC9047476 DOI: 10.1186/s12889-022-13218-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2022] [Accepted: 04/11/2022] [Indexed: 11/25/2022] Open
Abstract
Background Prostate cancer survivors (PCS) experience long-term side effects beyond treatment such as fatigue, depression and anxiety. Quality and engaging supportive care programs are needed to reduce these chronic and debilitating effects. Independent of physical activity (PA), high volumes of sedentary behavior (SB) are associated with chronic disease-related risk factors and poorer cancer-specific quality of life (QoL). Simultaneously increasing PA and decreasing SB may be an effective health promotion strategy. Given that PCS may face several barriers to engaging in supervised programs, there is a need to develop and assess the efficacy of interventions that employ distance-based approaches for behavior change. The primary aim of this study is to determine the effects of a 12-week intervention (Fitbit + behavioral counselling) vs. Fitbit-only control group in reducing SB among PCS. Secondary outcomes include light-intensity PA, QoL, motivational outcomes, and patient satisfaction. Methods This two-armed, randomized controlled trial will recruit inactive PCS (stage I-IV) across Canada who self-report engaging in >8 hours/day of SB. Participants will be randomized to the intervention (n=60; Fitbit and behavioral support) or active control group (n=60; Fitbit-only). The intervention consists of the use of a Fitbit and a series of six behavioral support sessions (two group, four individual) to aid PCS in gradually replacing SB with light-intensity PA by increasing their daily step counts to 3,000 steps above their baseline values. The Fitbit-only control condition will receive a Fitbit and public health PA resources. The primary outcome is change in SB measured objectively using activPAL inclinometers. All secondary outcomes will be measured via self-report, except for PA which will be measuring using Fitbits. Data will be collected at baseline, post-intervention, and at 6-month post-intervention. Discussion Reducing SB and increasing light-intensity PA plays an important, yet often undervalued role in the health and well-being of PCS. This study will create a unique distance-based platform that can be used by clinical and community-based organizations as a low-cost, supportive care tool to improve health outcomes for PCS. Trial Registration ClinicalTrials.gov Identifier NCT05214937. Registered January 28, 2022 Protocol version: v.1
Collapse
Affiliation(s)
- Linda Trinh
- Faculty of Kinesiology and Physical Education, University of Toronto, 55 Harbord Street, Toronto, Ontario, M5S 2W6, Canada.
| | - Catherine M Sabiston
- Faculty of Kinesiology and Physical Education, University of Toronto, 55 Harbord Street, Toronto, Ontario, M5S 2W6, Canada
| | - Shabbir M H Alibhai
- Faculty of Medicine, University of Toronto, 1 King's College Circle, Medical Sciences Building, Toronto, ON, M5S 1A8, Canada.,Toronto General Research Institute, Toronto General Hospital, 200 Elizabeth St, Toronto, ON, M5G 2C4, Canada
| | - Jennifer M Jones
- Department of Supportive Care, Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2C1, Canada
| | - Kelly P Arbour-Nicitopoulos
- Faculty of Kinesiology and Physical Education, University of Toronto, 55 Harbord Street, Toronto, Ontario, M5S 2W6, Canada
| | - Daniel Santa Mina
- Faculty of Kinesiology and Physical Education, University of Toronto, 55 Harbord Street, Toronto, Ontario, M5S 2W6, Canada
| | - Kristin Campbell
- Department of Physical Therapy, University of British Columbia, 2177 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada
| | - Guy E Faulkner
- School of Kinesiology, University of British Columbia, 210-6081 University Boulevard, Vancouver, BC, V6T 1Z1, Canada
| |
Collapse
|
9
|
Stoner B, Cao X, Kolodziej A, Villegas-Galaviz J, Campbell K, Thompson M, Birks E, Vaidya G. Bedside Ultrasound of Internal Jugular Vein for Right Ventricular Function Assessment. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
10
|
Campbell K, Velazquez O, Sullivan J, Lipshultz L. Finasteride-Associated Suicide and Depression in Men Treated for Hypogonadism and Impotence. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.01.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
11
|
Campbell K, Velazquez O, Sullivan J, Lipshultz L. Is Testosterone Really Your Sex Hormone: Sexual practices as Defined by Testosterone Concentration. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.01.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
12
|
Held PK, Campbell K, Wiberley-Bradford AE, Lasarev M, Horner V, Peterson A. Analytical Validation of Familial Hypercholesterolemia Biomarkers in Dried Blood Spots. Int J Neonatal Screen 2022; 8:ijns8010014. [PMID: 35225936 PMCID: PMC8883967 DOI: 10.3390/ijns8010014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 02/01/2022] [Accepted: 02/05/2022] [Indexed: 12/07/2022] Open
Abstract
Heterozygous familial hypercholesterolemia (HeFH) is a common, treatable genetic disorder characterized by premature atherosclerosis and cardiovascular disease, yet the majority of affected individuals remain undiagnosed. Newborn screening could play a role in identification of at-risk individuals and provide an opportunity for early intervention, prior to the onset of symptoms. The objective of this study was to develop and validate assays for quantification of candidate HeFH biomarkers in dried blood spots (DBS). Commercially available enzyme assay kits for quantification of serum total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) were modified for high-throughput analysis of DBS. Apolipoprotein B (ApoB) concentrations in DBS were measured using an immunoassay with modifications from published studies. All three assays were validated according to the College of American Pathologists guidelines for clinical laboratories. The performance of TC, LDL-C, and ApoB assays was assessed by precision, recovery, limit of quantification (LOQ) and linearity. Precision studies yielded coefficients of variation (CV) of less than 15%, with recovery greater than 75% for all three assays. The determined LOQ and linearity were comparable to serum-based assays. In a direct comparison between serum and DBS concentrations, positive correlations were demonstrated for TC, LDL-C, and ApoB. Additionally, the initial evaluation of the three biomarker concentrations within the unaffected population was similar to values obtained in previous published studies. This study reports on methods for quantification of TC, LDL-C, and ApoB in DBS. Assay validation results were within acceptable limits for newborn screening. This is an important first step toward the identification of newborns with HeFH.
Collapse
Affiliation(s)
- Patrice K. Held
- Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA;
- Wisconsin State Laboratory of Hygiene, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA; (K.C.); (A.E.W.-B.)
- Correspondence: ; Tel.: +1-608-265-5968
| | - Kristin Campbell
- Wisconsin State Laboratory of Hygiene, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA; (K.C.); (A.E.W.-B.)
| | - Amy E. Wiberley-Bradford
- Wisconsin State Laboratory of Hygiene, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA; (K.C.); (A.E.W.-B.)
| | - Michael Lasarev
- Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA;
| | - Vanessa Horner
- Department of Pathology, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA;
| | - Amy Peterson
- Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA;
| |
Collapse
|
13
|
Deshayes S, Leite Ferreira D, Madelaine J, Oulkhouir Y, Campbell K, Fouquet H, Teulier S, Magnier R, Heyndrickx M, Lerouge D, Bergot E, Justet A. [D-CBP study: Evaluation of lung cancer management times]. Rev Mal Respir 2021; 38:894-903. [PMID: 34756617 DOI: 10.1016/j.rmr.2021.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Accepted: 07/28/2021] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Lung cancer is the leading cause of cancer-related death. Delays may have an impact on patient survival. The objective of this study was to evaluate the diagnostic and therapeutic management times for patients admitted for lung cancer treatment in the Respiratory Department of CHU de Caen Normandie. MATERIALS AND METHODS This is a retrospective, single-center and observational study, conducted on all patients treated for lung cancer from June 2017 to January 2018 in our department of pneumology in the Caen Normandie CHU. The main median times were investigated were: Global Time (abnormal imaging-treatment), Diagnosis time (abnormal imaging-diagnosis) and Treatment Time (diagnosis-treatment). RESULTS One hundred and twenty-seven (127) patients were included. Median global time was 55.5 days [31,25; 393], median diagnosis time was 22 days [13; 49], and median treatment time was 24.5 days [12,25; 45]. DISCUSSION Our treatment times are consistent with those previously published. Areas for improvement are being developed in accordance with the 2014-2019 cancer plan, in particularly the creation in our institution of a specific care pathway for patients with lung cancer.
Collapse
Affiliation(s)
- S Deshayes
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - D Leite Ferreira
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - J Madelaine
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - Y Oulkhouir
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - K Campbell
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - H Fouquet
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - S Teulier
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - R Magnier
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - M Heyndrickx
- Service de Chirurgie Thoracique, CHU de Caen, 14000 Caen, France
| | - D Lerouge
- Service de Radiothérapie, Centre de Lutte contre le Cancer François Baclesse, 14000 Caen, France
| | - E Bergot
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France; ISTCT, UMR6030-CNRS-CEA-Université de Caen, 14000 Caen, France
| | - A Justet
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France; ISTCT, UMR6030-CNRS-CEA-Université de Caen, 14000 Caen, France.
| |
Collapse
|
14
|
Blaivas M, Blaivas L, Campbell K, Liu Y. 139 Creating an Automated Artificial Intelligence Left Ventricular Ejection Fraction Estimator for Parasternal Long Axis Scans from Unrelated Apical Window Echo Videos. Ann Emerg Med 2021. [DOI: 10.1016/j.annemergmed.2021.09.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Campbell K. CN25 The haemato-oncology patient experience of the process of palliative care: A constructivist grounded theory study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
16
|
Messer LH, Campbell K, Pyle L, Forlenza GP. Basal-IQ technology in the real world: satisfaction and reduction of diabetes burden in individuals with type 1 diabetes. Diabet Med 2021; 38:e14381. [PMID: 32767401 DOI: 10.1111/dme.14381] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2020] [Revised: 07/08/2020] [Accepted: 07/28/2020] [Indexed: 12/21/2022]
Abstract
AIM To describe person-reported outcomes of the Basal-IQ predictive low-glucose-suspend system (Tandem Diabetes Care, San Diego, CA, USA) in real-world use. METHODS Adults with type 1 diabetes/caregivers of minors with type 1 diabetes completed the Diabetes Impact and Device Satisfaction questionnaire (11 items scored on 10-point Likert scales) prior to Basal-IQ system initiation, and at 2, 4 and 6 months post-initiation. Analysis was stratified by previous insulin treatment method. Beta mixed models were used to measure change in device satisfaction (e.g. trust, ease of use) and diabetes impact (e.g. hypoglycaemia fear, poor sleep) scores between time points, adjusting for baseline covariates. RESULTS A total of 967 adults and caregivers [54% women, mean (sd) age 36 (17) years, 57% Tandem pump users, 27% non-Tandem pump users, 17% multiple daily injection users] completed surveys. Device satisfaction significantly increased from baseline to 2 months in all groups (P<0.001 multiple daily injection and non-Tandem pump users; P=0.048 Tandem pump users), and was sustained from 2 to 6 months in all groups. Diabetes impact decreased significantly from baseline to 2 months in all groups (P<0.001 for all), was sustained from 2 to 6 months in multiple daily injection and Tandem pump users, and increased slightly at 4 months/decreased at 6 months in non-Tandem users. CONCLUSION The Basal-IQ system increased device satisfaction and reduced diabetes impact in all users in the first 2 months of use, and satisfaction was sustained over 6 months, with small fluctuations.
Collapse
Affiliation(s)
- L H Messer
- Barbara Davis Center, University of Colorado Anschutz, Aurora, CO, USA
| | - K Campbell
- Barbara Davis Center, University of Colorado Anschutz, Aurora, CO, USA
| | - L Pyle
- Barbara Davis Center, University of Colorado Anschutz, Aurora, CO, USA
| | - G P Forlenza
- Barbara Davis Center, University of Colorado Anschutz, Aurora, CO, USA
| |
Collapse
|
17
|
Kuerbitz J, Madhavan M, Ehrman LA, Kohli V, Waclaw RR, Campbell K. Temporally Distinct Roles for the Zinc Finger Transcription Factor Sp8 in the Generation and Migration of Dorsal Lateral Ganglionic Eminence (dLGE)-Derived Neuronal Subtypes in the Mouse. Cereb Cortex 2020; 31:1744-1762. [PMID: 33230547 DOI: 10.1093/cercor/bhaa323] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 10/07/2020] [Accepted: 10/07/2020] [Indexed: 12/29/2022] Open
Abstract
Progenitors in the dorsal lateral ganglionic eminence (dLGE) are known to give rise to olfactory bulb (OB) interneurons and intercalated cells (ITCs) of the amygdala. The dLGE enriched transcription factor Sp8 is required for the normal generation of ITCs as well as OB interneurons, particularly the calretinin (CR)-expressing subtype. In this study, we used a genetic gain-of-function approach in mice to examine the roles Sp8 plays in controlling the development of dLGE-derived neuronal subtypes. Misexpression of Sp8 throughout the ventral telencephalic subventricular zone (SVZ) from early embryonic stages, led to an increased generation of ITCs which was dependent on Tshz1 gene dosage. Additionally, Sp8 misexpression impaired rostral migration of OB interneurons with clusters of CR interneurons seen in the SVZ along with decreased differentiation of calbindin OB interneurons. Sp8 misexpression throughout the ventral telencephalon also reduced ventral LGE neuronal subtypes including striatal projection neurons. Delaying Sp8 misexpression until E14-15 rescued the striatal and amygdala phenotypes but only partially rescued OB interneuron reductions, consistent with an early window of striatal and amygdala neurogenesis and ongoing OB interneuron generation at this late stage. Our results demonstrate critical roles for the timing and neuronal cell-type specificity of Sp8 expression in mouse LGE neurogenesis.
Collapse
Affiliation(s)
- J Kuerbitz
- Divisions of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.,Medical-Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
| | - M Madhavan
- Divisions of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - L A Ehrman
- Divisions of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.,Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
| | - V Kohli
- Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
| | - R R Waclaw
- Divisions of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.,Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
| | - K Campbell
- Divisions of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.,Divisions of Neurosurgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
| |
Collapse
|
18
|
Davidson N, Campbell K, Foroughi F, Tayal V, Lynar S, Crawford LC, Kidd SE, Baird R, Davies J, Meumann EM. Disseminated Saksenaea infection in an immunocompromised host associated with a good clinical outcome: a case report and review of the literature. BMC Infect Dis 2020; 20:755. [PMID: 33054720 PMCID: PMC7559758 DOI: 10.1186/s12879-020-05459-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2019] [Accepted: 09/29/2020] [Indexed: 11/24/2022] Open
Abstract
Background Saksenaea species (spp.) are uncommon causes of mucormycosis but are emerging pathogens mostly associated with trauma and soil contamination often in immunocompetent hosts. Due to lack of sporulation in the laboratory, diagnosis and susceptibility testing is difficult so optimal treatment regimens are unknown. Case presentation A 67 year-old man from the Northern Territory in Australia, with a history of eosinophilic granulomatosis with polyangiitis, developed disseminated Saksenaea infection after initially presenting with symptoms consistent with bacterial pyelonephritis. Despite a delay in diagnosis; with aggressive surgical management and dual therapy with amphotericin B and posaconazole, he survived. Conclusions We describe an unusual case of disseminated infection with a favourable outcome to date.
Collapse
Affiliation(s)
- N Davidson
- Division of Medicine, Royal Darwin Hospital, Darwin, Australia. .,Sullivan and Nicolaides Pathology, Brisbane, Australia.
| | - K Campbell
- Division of Medicine, Royal Darwin Hospital, Darwin, Australia
| | - F Foroughi
- Department of Pathology, Royal Darwin Hospital, Darwin, Australia
| | - V Tayal
- Division of Medicine, Royal Darwin Hospital, Darwin, Australia
| | - S Lynar
- Division of Medicine, Royal Darwin Hospital, Darwin, Australia.,Global and Tropical Health Division, Charles Darwin University, Menzies School of Health Research, Darwin, Australia
| | - L C Crawford
- National Mycology Reference Centre, Microbiology and Infectious Diseases, SA Pathology, Frome Road, Adelaide, South Australia, Australia
| | - S E Kidd
- National Mycology Reference Centre, Microbiology and Infectious Diseases, SA Pathology, Frome Road, Adelaide, South Australia, Australia
| | - R Baird
- Department of Pathology, Royal Darwin Hospital, Darwin, Australia
| | - J Davies
- Division of Medicine, Royal Darwin Hospital, Darwin, Australia.,Global and Tropical Health Division, Charles Darwin University, Menzies School of Health Research, Darwin, Australia
| | - E M Meumann
- Division of Medicine, Royal Darwin Hospital, Darwin, Australia.,Global and Tropical Health Division, Charles Darwin University, Menzies School of Health Research, Darwin, Australia
| |
Collapse
|
19
|
Nolan P, Auer S, Spehar A, Oplatowska-Stachowiak M, Campbell K. Evaluation of Mass Sensitive Micro-Array biosensors for their feasibility in multiplex detection of low molecular weight toxins using mycotoxins as model compounds. Talanta 2020; 222:121521. [PMID: 33167231 DOI: 10.1016/j.talanta.2020.121521] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Revised: 08/03/2020] [Accepted: 08/05/2020] [Indexed: 12/22/2022]
Abstract
Mycotoxins produced by Fusarium species including trichothecenes, zearalenone and fumonisins, can co-contaminate food and feed throughout the supply chain, including cereal grains and animal feeds. There is an increasing demand to enhance global food security by improving the monitoring of mycotoxins throughout our food supply chain. For time and cost-efficient analysis, rapid tests capable of detecting multiple toxins from a single sample are ideal. Considering these current trends in mycotoxin testing, this project examined the feasibility of using both a portable and non-portable mass-based biosensor for multiplex mycotoxin detection. The biosensor was a mass sensitive microarray (MSMA) which consisted of 4 × 16 miniaturized mass sensitive transducer pixels based on solidly mounted resonator (SMR) technology. Functionalisation of individual pixels on the sensor surface using nano-spotting technology for the simultaneous and semi-quantitative detection of three regulated mycotoxins: T2-toxin (T2) zearalenone (ZEN), and fumonisin B1 (FumB1) was examined. With the integration of portable and non-portable microfluidic devices for antibody and standard sample injections, competitive inhibition assays were developed followed by singleplex and multiplex calibration curves. The characteristics and performance of the MSMA were evaluated including sensitivity which was determined as the concentration causing 50% inhibition. Sensitivity of singleplex assays using the portable microfluidic device (PMD) were 1.3 ng/ml, 2.0 ng/ml and 6.8 ng/ml for T2, FumB1 and ZEN, respectively. Sensitivity of the multiplex assay again using the PMD was 6.1 ng/ml, 3.6 ng/ml and 2.4 ng/ml for T2, FumB1 and ZEN, respectively. The PMD was an easy to use and highly sensitive screening tool which has been demonstrated for the multiplex detection of three regulated mycotoxins. Analysis was in real time and results were fully digital. Since detection of analytes was by mass it was both a label-free and cost-efficient method proposed method of analysis for mycotoxins.
Collapse
Affiliation(s)
- P Nolan
- Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, 19 Chlorine Gardens, Belfast, UK, BT9 5DL
| | - S Auer
- BioMensio Limited, Hermiankatu 6-8H, 33720, Tampere, Finland
| | - A Spehar
- BioMensio Limited, Hermiankatu 6-8H, 33720, Tampere, Finland
| | - M Oplatowska-Stachowiak
- Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, 19 Chlorine Gardens, Belfast, UK, BT9 5DL
| | - K Campbell
- Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, 19 Chlorine Gardens, Belfast, UK, BT9 5DL.
| |
Collapse
|
20
|
Kirkham AA, Bland KA, Wollmann H, Bonsignore A, McKenzie DC, Van Patten C, Gelmon KA, Campbell K. Maintenance of Fitness and Quality-of-Life Benefits From Supervised Exercise Offered as Supportive Care for Breast Cancer. J Natl Compr Canc Netw 2020; 17:695-702. [PMID: 31200349 DOI: 10.6004/jnccn.2018.7276] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2018] [Accepted: 01/17/2019] [Indexed: 11/17/2022]
Abstract
BACKGROUND Overwhelming randomized controlled trial evidence demonstrates that exercise has positive health impacts during and after treatment for breast cancer. Yet, evidence generated by studies in which exercise programs are delivered outside a tightly controlled randomized trial setting is limited. The purpose of this study was to assess the effectiveness of an evidence-based exercise program with real-world implementation on physical fitness and quality of life (QoL). PATIENTS AND METHODS Oncologists referred women with early-stage breast cancer who were scheduled to receive adjuvant chemotherapy. The program consisted of supervised aerobic and resistance exercise of moderate to vigorous intensity 3 times per week until the end of treatment (chemotherapy ± radiotherapy), then twice per week for 10 weeks, followed by once per week for 10 weeks. Health-related physical fitness and QoL were assessed at baseline, end of treatment, end of program, and 1-year follow-up. RESULTS A total of 73 women were enrolled. Estimated peak VO2 (VO2peak), QoL, and body weight were maintained between baseline and end of treatment, whereas muscular strength improved (P<.01). By the end of the program, VO2peak, heart rate recovery, waist circumference, and some aspects of QoL were improved (all P<.01) relative to baseline. One year later, VO2peak, QoL, and waist circumference were maintained relative to end of program, whereas the improvements in strength and heart rate recovery had dissipated (all P<.01). CONCLUSIONS Evidence-based exercise programming delivered with real-world implementation maintained VO2peak, strength, and QoL during adjuvant treatment and improved these measures after treatment completion among women with breast cancer. Continued guidance and support may be required for long-term maintenance of strength improvements in this population.
Collapse
Affiliation(s)
| | | | - Holly Wollmann
- University of British Columbia, Vancouver, British Columbia, Canada
| | | | - Don C McKenzie
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Cheri Van Patten
- British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Karen A Gelmon
- British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Kristin Campbell
- University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
21
|
Van Tiggelen H, LeBlanc K, Campbell K, Woo K, Baranoski S, Chang Y, Dunk A, Gloeckner M, Hevia H, Holloway S, Idensohn P, Karadağ A, Koren E, Kottner J, Langemo D, Ousey K, Pokorná A, Romanelli M, Santos V, Smet S, Tariq G, Van den Bussche K, Van Hecke A, Verhaeghe S, Vuagnat H, Williams A, Beeckman D. Standardizing the classification of skin tears: validity and reliability testing of the International Skin Tear Advisory Panel Classification System in 44 countries. Br J Dermatol 2020; 183:146-154. [PMID: 31605618 PMCID: PMC7384145 DOI: 10.1111/bjd.18604] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/06/2019] [Indexed: 01/21/2023]
Abstract
BACKGROUND Skin tears are acute wounds that are frequently misdiagnosed and under-reported. A standardized and globally adopted skin tear classification system with supporting evidence for diagnostic validity and reliability is required to allow assessment and reporting in a consistent way. OBJECTIVES To measure the validity and reliability of the International Skin Tear Advisory Panel (ISTAP) Classification System internationally. METHODS A multicountry study was set up to validate the content of the ISTAP Classification System through expert consultation in a two-round Delphi procedure involving 17 experts from 11 countries. An online survey including 24 skin tear photographs was conducted in a convenience sample of 1601 healthcare professionals from 44 countries to measure diagnostic accuracy, agreement, inter-rater reliability and intrarater reliability of the instrument. RESULTS A definition for the concept of a 'skin flap' in the area of skin tears was developed and added to the initial ISTAP Classification System consisting of three skin tear types. The overall agreement with the reference standard was 0·79 [95% confidence interval (CI) 0·79-0·80] and sensitivity ranged from 0·74 (95% CI 0·73-0·75) to 0·88 (95% CI 0·87-0·88). The inter-rater reliability was 0·57 (95% CI 0·57-0·57). The Cohen's Kappa measuring intrarater reliability was 0·74 (95% CI 0·73-0·75). CONCLUSIONS The ISTAP Classification System is supported by evidence for validity and reliability. The ISTAP Classification System should be used for systematic assessment and reporting of skin tears in clinical practice and research globally. What's already known about this topic? Skin tears are common acute wounds that are misdiagnosed and under-reported too often. A skin tear classification system is needed to standardize documentation and description for clinical practice, audit and research. What does this study add? The International Skin Tear Advisory Panel Classification System was psychometrically tested in 1601 healthcare professionals from 44 countries. Diagnostic accuracy was high when differentiating between type 1, 2 and 3 skin tears using a set of validated photographs.
Collapse
|
22
|
Zhang L, Fekete N, Campbell K. 3D MSC Culture in Saint-Gobain VueLife® FEP Bags Using Microcarriers. Cytotherapy 2020. [DOI: 10.1016/j.jcyt.2020.04.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Taleb I, Wever-Pinzon O, Yin M, Kfoury A, Caine W, Stehlik J, Catino A, Wever-Pinzon J, Bonios M, McKellar S, Alharethi R, Koliopoulou A, Fang J, Selzman C, Dranow E, Shah P, Singh R, Psotka M, Zhu W, Slaughter M, Birks E, Koenig S, Kanwar M, Kyvernitakis A, Hoffman K, Guglin M, Kotter J, Campbell K, Drakos S. Predicting Cardiac Structural and Functional Improvement Induced by Mechanical Unloading in Chronic Heart Failure: A Derivation-Validation Multicenter Study. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
24
|
Pérez-Díaz IM, Dickey AN, Fitria R, Ravishankar N, Hayes J, Campbell K, Arritt F. Modulation of the bacterial population in commercial cucumber fermentations by brining salt type. J Appl Microbiol 2020; 128:1678-1693. [PMID: 31997433 DOI: 10.1111/jam.14597] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 01/06/2020] [Accepted: 01/21/2020] [Indexed: 11/28/2022]
Abstract
AIMS Differences in the bacterial population of cucumber fermentations brined with no salt, 100 mmol l-1 (1·1%) calcium chloride (CaCl2 ) or 1·03 mol l-1 (6%) sodium chloride (NaCl) were studied. METHODS AND RESULTS Changes in the microbiology and chemistry of commercial and laboratory scale cucumber fermentations occurring as a function of time were monitored using colony counts and metagenetic analysis, and a pH probe and high-performance liquid chromatography analysis respectively. Dissolved oxygen and carbon dioxide content were monitored in commercial fermentations. Fermentations brined with calcium chloride (CaCl2 ) or no salt sustained faster microbial growth and reduction in pH than those brined with 1·03 mol l-1 NaCl. Leuconostoc, Lactococcus and Weissella dominated in fermentations brined with no salt or 100 mmol l-1 CaCl2 on day 1 as compared to Weissella and enterobacteria in fermentations containing 1·03 mol l-1 NaCl. Lactobacilli dominated all fermentations by the third day, regardless of salt type, and was followed, in relative abundance by Pediococcus, Leuconostoc, Lactococcus and Weissella. From 84 to 96% of the population was composed of Lactobacillus by day 7 of the fermentations, except in the no salt fermentations in which a mixed population of LAB remained. The population of LAB found in commercial cucumber fermentations brined with 100 mmol l-1 CaCl2 (n = 18) or 1·03 mol l-1 NaCl (n = 9) mimicked that of laboratory fermentations. A declining population of aerobes was detected in commercial fermentations brined with CaCl2 on day 1. CONCLUSION A reduced NaCl content in cucumber fermentation enhances microbial diversity. SIGNIFICANCE AND IMPACT OF THE STUDY This study fills a knowledge gap and aids in the design of improved reduced NaCl cucumber fermentations.
Collapse
Affiliation(s)
- I M Pérez-Díaz
- Food Science Research Unit, USDA-Agricultural Research Service, SEA, Raleigh, NC, USA
| | - A N Dickey
- Bioinformatics Research Center, North Carolina State University, Raleigh, NC, USA
| | - R Fitria
- Department of Food, Bioprocessing, and Nutrition Sciences, North Carolina State University, Raleigh, NC, USA
| | - N Ravishankar
- Department of Food, Bioprocessing, and Nutrition Sciences, North Carolina State University, Raleigh, NC, USA
| | - J Hayes
- Food Science Research Unit, USDA-Agricultural Research Service, SEA, Raleigh, NC, USA
| | - K Campbell
- Mount Olive Pickle Company, Mount Olive, NC, USA
| | - F Arritt
- Mount Olive Pickle Company, Mount Olive, NC, USA
| |
Collapse
|
25
|
Bartholomew JB, Campbell K, Moore JB. The Potential and Peril of Pilot Research: Editorial Guidelines to Maintain Transparency and Reduce Overinterpretation of Effects. Transl J ACSM 2020. [DOI: 10.1249/tjx.0000000000000139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
26
|
Tsagkaris A, Nelis J, Ross G, Jafari S, Guercetti J, Kopper K, Zhao Y, Rafferty K, Salvador J, Migliorelli D, Salentijn G, Campbell K, Marco M, Elliot C, Nielen M, Pulkrabova J, Hajslova J. Critical assessment of recent trends related to screening and confirmatory analytical methods for selected food contaminants and allergens. Trends Analyt Chem 2019. [DOI: 10.1016/j.trac.2019.115688] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
27
|
de Winter J, Yuen M, Van der Pijl R, Li F, Shengyi S, Conijn S, Van de Locht M, Bogaards S, van Kleef E, Bryson-Richardson R, Campbell K, Ma W, Irving T, Malfatti E, Granzier H, van Engelen B, Voermans N, Ottenheijm C. P.162Novel Kbtbd13R408C-knockin mouse model phenocopies NEM6 myopathy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
SAGLIMBENE V, Wong G, Teixeira-Pinto A, Ruospo M, Palmer S, Garcia-Larsen V, Campbell K, Craig J, Hegbrant J, Strippoli G. SUN-052 DIETARY PATTERNS AND MORTALITY IN ADULTS ON HEMODIALYSIS. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
29
|
Puckrein G, Xu L, Ryan A, Campbell K, Balu S. Abstract P5-15-06: Potential Medicare beneficiary out-of-pocket cost reductions through use of biosimilar filgrastim-sndz over reference filgrastim among breast cancer patients: A simulation model analysis. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-15-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Rationale & Objective: Granulocyte colony-stimulating factors (G-CSFs) are utilized to decrease the incidence of febrile neutropenia (FN) in patients with cancers undergoing chemotherapy treatments. In 2015 biosimilar filgrastim-sndz was the first biosimilar to be approved and launched in the US market. Limited data exists in ascertaining the impact of biosimilars on patient out-of-pocket (OOP) expenditures. The objective of this simulation model was to estimate potential OOP cost savings through use of filgrastim-sndz over reference filgrastim from a Medicare breast cancer patient perspective.
Methods: An Excel simulation analysis was conducted among breast cancer patients treated with biosimilar filgrastim-sndz or the branded reference filgrastim (identified through HCPCS codes). Data from the 2016 Medicare Limited Data Set (5% sample of the carrier file) was used to populate the model. The payment calculation worksheet within the Medicare carrier file was used to calculate the average Medicare payment to the provider and the average beneficiary OOP responsibility per claim of either filgrastim-sndz or reference filgrastim. The average OOP reduction per claim for a filgrastim-sndz beneficiary relative to a reference filgrastim beneficiary was multiplied to a hypothetical FN prevalent population of 100,000 beneficiaries (average of 10 claims per beneficiary) to estimate the potential OOP savings.
Results: Data for 616 filgrastim-sndz and 1,064 reference filgrastim claims were used to populate the model. The average Medicare allowed charge amount per claim for a filgrastim-sndz beneficiary was $362.8 versus $406.9 for a reference filgrastim beneficiary, while corresponding average Medicare payments to the provider were $284.1 and $316.9, respectively. On an average, OOP responsibility for a filgrastim-sndz beneficiary was lower compared to a reference filgrastim beneficiary ($72.9 versus $82.5) leading to a cost saving per claim of $9.60. When extrapolated to 100,000 beneficiaries (1,000,000 claims), the overall cost saving was projected to be around $9.6 million.
Conclusions: Our simulation model estimated a potential OOP Medicare breast cancer beneficiary saving of around $9.6 million, based on a hypothetical population of 100,000 FN beneficiaries, with the use of biosimilar filgrastim-sndz over reference filgrastim. Further real-world analyses are required to evaluate the true cost saving potential from a breast cancer patient perspective with the use of biosimilars over reference biologics.
Citation Format: Puckrein G, Xu L, Ryan A, Campbell K, Balu S. Potential Medicare beneficiary out-of-pocket cost reductions through use of biosimilar filgrastim-sndz over reference filgrastim among breast cancer patients: A simulation model analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-15-06.
Collapse
Affiliation(s)
- G Puckrein
- National Minority Quality Forum, Washington, DC; Sandoz Inc., Princeton
| | - L Xu
- National Minority Quality Forum, Washington, DC; Sandoz Inc., Princeton
| | - A Ryan
- National Minority Quality Forum, Washington, DC; Sandoz Inc., Princeton
| | - K Campbell
- National Minority Quality Forum, Washington, DC; Sandoz Inc., Princeton
| | - S Balu
- National Minority Quality Forum, Washington, DC; Sandoz Inc., Princeton
| |
Collapse
|
30
|
Nelis JLD, Tsagkaris AS, Zhao Y, Lou-Franco J, Nolan P, Zhou H, Cao C, Rafferty K, Hajslova J, Elliott CT, Campbell K. The end user sensor tree: An end-user friendly sensor database. Biosens Bioelectron 2019; 130:245-253. [PMID: 30769289 DOI: 10.1016/j.bios.2019.01.055] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 01/21/2019] [Accepted: 01/22/2019] [Indexed: 11/18/2022]
Abstract
Detailed knowledge regarding sensor based technologies for the detection of food contamination often remains concealed within scientific journals or divided between numerous commercial kits which prevents optimal connectivity between companies and end-users. To overcome this barrier The End user Sensor Tree (TEST) has been developed. TEST is a comprehensive, interactive platform including over 900 sensor based methods, retrieved from the scientific literature and commercial market, for aquatic-toxins, mycotoxins, pesticides and microorganism detection. Key analytical parameters are recorded in excel files while a novel classification system is used which provides, tailor-made, experts' feedback using an online decision tree and database introduced here. Additionally, a critical comparison of reviewed sensors is presented alongside a global perspective on research pioneers and commercially available products. The lack of commercial uptake of the academically popular electrochemical and nanomaterial based sensors, as well as multiplexing platforms became very apparent and reasons for this anomaly are discussed.
Collapse
Affiliation(s)
- J L D Nelis
- Institute for Global Food Security, School of Biological Sciences, Queen's University, David Keir Building, Stranmillis Road, Belfast BT9 5AG, UK
| | - A S Tsagkaris
- Department of Food Analysis and Nutrition, Faculty of Food and Biochemical Technology, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6 - Dejvice, Prague, Czech Republic
| | - Y Zhao
- Institute for Global Food Security, School of Biological Sciences, Queen's University, David Keir Building, Stranmillis Road, Belfast BT9 5AG, UK; School of Electronics, Electrical Engineering and Computer Science, Queen's University Belfast, Stranmillis Road, Belfast, UK
| | - J Lou-Franco
- Institute for Global Food Security, School of Biological Sciences, Queen's University, David Keir Building, Stranmillis Road, Belfast BT9 5AG, UK
| | - P Nolan
- Institute for Global Food Security, School of Biological Sciences, Queen's University, David Keir Building, Stranmillis Road, Belfast BT9 5AG, UK
| | - H Zhou
- School of Electronics, Electrical Engineering and Computer Science, Queen's University Belfast, Stranmillis Road, Belfast, UK; Department of Informatics, University of Leicester, University Road, Leicester LE1 7RH, UK
| | - C Cao
- Institute for Global Food Security, School of Biological Sciences, Queen's University, David Keir Building, Stranmillis Road, Belfast BT9 5AG, UK
| | - K Rafferty
- School of Electronics, Electrical Engineering and Computer Science, Queen's University Belfast, Stranmillis Road, Belfast, UK
| | - J Hajslova
- Department of Food Analysis and Nutrition, Faculty of Food and Biochemical Technology, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6 - Dejvice, Prague, Czech Republic
| | - C T Elliott
- Institute for Global Food Security, School of Biological Sciences, Queen's University, David Keir Building, Stranmillis Road, Belfast BT9 5AG, UK
| | - K Campbell
- Institute for Global Food Security, School of Biological Sciences, Queen's University, David Keir Building, Stranmillis Road, Belfast BT9 5AG, UK.
| |
Collapse
|
31
|
O'Shea C, Brooks A, Campbell K, Hendriks J, Lau D, Sanders P. A Retrospective Analysis of Remote Monitoring Alerts for Atrial Fibrillation: Implications for Anticoagulation. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
32
|
O'Shea C, Campbell K, Hendriks J, Brooks A, Lau D, Sanders P. Remote Monitoring Alert Burden from Implantable Cardioverter Defibrillators: An Analysis of >4000 Patients. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
33
|
Setbo E, Campbell K, O'Cuiv P, Hubbard R. Utility of Probiotics for Maintenance or Improvement of Health Status in Older People - A Scoping Review. J Nutr Health Aging 2019; 23:364-372. [PMID: 30932135 DOI: 10.1007/s12603-019-1187-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE To evaluate the available evidence on probiotic use in older adults from human studies. DESIGN systematic review. METHODS The databases Embase, CINAHL and Medline were searched in December of 2017 for studies in humans where probiotics were used to modify a health outcome in older people. The quality of studies was evaluated using the Critical Appraisal Skills Program (CASP) assessment tool and the Cochrane Risk of Bias Assessment tool. PARTICIPANTS Subjects aged over sixty years either through specified selection criteria or where the mean participant age was greater than sixty. INTERVENTIONS Probiotic supplements. MEASUREMENTS Pre-specified clinically measurable health outcomes in age related conditions. RESULTS 1210 articles were identified. After quality assessment and selection criteria were applied, 33 articles were identified to be included for review. As these studies cover a variety of applications and used customised protocols accordingly, meta-analysis was not possible and synthesis is in narrative form. CONCLUSIONS A growing body of research has applied commercially available probiotic preparations across care settings for age related conditions including gut dysmotility, osteoporosis, common infectious diseases and cognitive impairment. Although methodologies vary, randomised controlled trials have reproduced results in these areas, and so warrant consideration of probiotics as a low risk adjuvant treatment for specific indications in the elderly.
Collapse
Affiliation(s)
- E Setbo
- Emerald Setbo, University of Queensland, Brisbane, Queensland Australia,
| | | | | | | |
Collapse
|
34
|
Edelstein K, Campbell K, Bernstein L, Lax I, Backhouse F, Pond G, Kalidindi N, Or R, Laperriere N, Millar BA, Shultz D, Berlin A, Zadeh G, Maurice C, Mason W. RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Kim Edelstein
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | | | - Lori Bernstein
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Ilyse Lax
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Felicity Backhouse
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | | | - Navya Kalidindi
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Rosemarylin Or
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Normand Laperriere
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Barbara-Ann Millar
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - David Shultz
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Alejandro Berlin
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Gelareh Zadeh
- Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada
| | - Catherine Maurice
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Warren Mason
- University of Toronto University Health Network, Toronto, ON, Canada
| |
Collapse
|
35
|
McBride A, Krendyukov A, Mathieson N, Campbell K, Balu S, MacDonald K, Abraham I. Cost simulation for the US of febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim in lung cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy444.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Simone B, Campbell K, Han Y, Li Y, Patay Z, Broniscer A, Merchant T, Tinkle C. Patterns of Disease Progression after Conformal Radiation Therapy for Diffuse Intrinsic Pontine Glioma. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
37
|
de Winter J, Molenaar J, van Willigenburg M, Conijn S, Lassche S, Irving T, Campbell K, Van Engelen B, Voermans N, Ottenheijm C. CONGENITAL MYOPATHIES: NEMALINE AND TITINOPATHIES. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
38
|
Rambla-Alegre M, Leonardo S, Barguil Y, Flores C, Caixach J, Campbell K, Elliott CT, Boundy MJ, Harwood T, Maillaud C, Campàs M, Diogene J. Dépistage rapide et confirmation du profil multitoxines des tétrodotoxines et de ses analogues dans les liquides biologiques. Toxicologie Analytique et Clinique 2018. [DOI: 10.1016/j.toxac.2018.04.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Holmqvist F, Rathakrishnan B, Jackson L, Campbell K, Daubert J. Pacemaker programming in patients with first-degree AV-block: Programming pattern and possible consequences. Health Sci Rep 2018; 1:e39. [PMID: 30623076 PMCID: PMC6266422 DOI: 10.1002/hsr2.39] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Accepted: 03/19/2018] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND The optimal way of pacing in patients with an indication for pacing and concomitant first-degree atrioventricular (AV)-block is not known, and consequently, firm guidelines on this topic are lacking. This study explored the current pacemaker programming pattern in patients with first-degree AV-block who have a dual chamber pacemaker without cardiac resynchronization. METHODS The study was a retrospective chart review conducted at Duke University Hospital. Patients receiving a pacemaker due to sinus node dysfunction with coexistent first-degree AV-block were studied. Baseline demographics and characteristics, as well as pacemaker programming parameters and follow-up data, were collected through chart review. Preimplantation and postimplantation electrocardiograms were analyzed. RESULTS A total of 74 patients were included (mean age, 75 ± 11 y; 53% men). The mean ± SD preimplant PR interval and QRS duration was 243 ± 46 and 110 ± 30 milliseconds, respectively. A history of atrial fibrillation was present in 49% of the patients, and 77% had a normal left ventricular ejection fraction. The majority of patients (65%) had their pacemakers programmed to atrial pacing (AAI/DDD +/-R), whereas 32% and 2.7% of the pacemakers were programmed to AV-sequential pacing (DDD) and ventricular pacing (VVI), respectively. There were no significant differences in baseline characteristics or electrocardiogram measures between patients programmed to the 3 pacing modes. Patients with pacemakers programmed to AAI had a lower ventricular pacing percentage at follow-up (8 vs 55, and 46% [DDD and VVI, respectively]; P < .001). CONCLUSIONS There was no evident association between baseline characteristics and programmed pacing mode in patients with first-degree AV-block. The choice of pacing mode affects long-term pacing burden, which in turn has been shown to influence outcome.
Collapse
Affiliation(s)
- F. Holmqvist
- Clinical Cardiac ElectrophysiologyDuke University Medical CenterDurhamNCUSA
- Department of CardiologyLund UniversityLundSweden
| | - B. Rathakrishnan
- Columbia University College of Physicians and SurgeonsNew York CityNYUSA
| | - L.R. Jackson
- Clinical Cardiac ElectrophysiologyDuke University Medical CenterDurhamNCUSA
| | - K. Campbell
- Department of PharmacyDuke University Medical CenterDurhamNCUSA
| | - J.P. Daubert
- Clinical Cardiac ElectrophysiologyDuke University Medical CenterDurhamNCUSA
| |
Collapse
|
40
|
Cullimore AM, Lester GD, Secombe CJ, Campbell K. Hypertrophic cardiomyopathy in a Clydesdale gelding. Aust Vet J 2018; 96:212-215. [DOI: 10.1111/avj.12701] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Revised: 10/04/2017] [Accepted: 11/22/2017] [Indexed: 01/23/2023]
Affiliation(s)
- AM Cullimore
- College of Veterinary Medicine, School of Veterinary and Life Sciences; Murdoch University; Murdoch Western Australia Australia
| | - GD Lester
- College of Veterinary Medicine, School of Veterinary and Life Sciences; Murdoch University; Murdoch Western Australia Australia
| | - CJ Secombe
- College of Veterinary Medicine, School of Veterinary and Life Sciences; Murdoch University; Murdoch Western Australia Australia
| | - K Campbell
- College of Veterinary Medicine, School of Veterinary and Life Sciences; Murdoch University; Murdoch Western Australia Australia
| |
Collapse
|
41
|
McBride A, Campbell K, Bikkina M, MacDonald K, Abraham I, Balu S. Abstract P4-12-07: Cost-minimization of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar ZARXIO® over NEUPOGEN®, NEULASTA®, and NEULASTA/ONPRO®: Breast cancer case study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-12-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
RATIONALE & OBJECTIVES: Biosimilar filgrastim may offer significant cost advantages over originator filgrastim and pegfilgrastim. The objectives were (1) to evaluate for the US the comparative cost-minimization of chemotherapy-induced (febrile) neutropenia (CIN/FN) prophylaxis with biosimilar filgrastim ZARZIO® over originator filgrastim NEUPOGEN®, and originator pegfilgrastim NEULASTA® and NEULASTA/ONPRO® injection device with the health-care provider (HP) providing full administration, using 3Q2016 average selling price (ASP); and (2) to apply the different savings estimates to a breast cancer case study.
METHODS: Cost-minimization analysis of [1] acquisition costs for one patient for one chemotherapy cycle for 1 to 14 days (d) using per unit dose, and [2] administration costs using Current Procedural Terminology (CPT) codes. We calculated [1] the general cost of prophylaxis for one cycle with each agent, with standard filgrastim administrations ranging from 1-14 days and pegfilgrastim limited to single administration; and [2] the cost-savings that could be accrued from 1-14d prophylaxis with ZARXIO® over the three originator options. The case study concerns a 43 y/o Caucasian female, newly diagnosed with stage 2 HER2-negative breast cancer being started on TAC (FN risk >20%); unremarkable medical history; no comorbidities; with primary prophylaxis initiated in cycle 1 and continued through 6 cycles per local protocol (single NEULASTA® or NEULASTA/ONPRO® or 11d NEUPOGEN® or ZARXIO®).
RESULTS: Using ASP+CPT, prophylaxis cost per dose (rounded) was $260 for ZARXIO®, $326 for NEUPOGEN®, $3,926 for NEULASTA®; $3,910 for NEULASTA®. In general, cost-savings per cycle from ZARXIO® over NEUPOGEN® ranged from $65 (1d) to $916 (14d); over Neulasta®, from $3,666 (1d) to $284 (14d); and over NEULASTA/ONPRO®, from $3,649 (1d) to $267 (14d). In the breast cancer case study, cost of prophylaxis per one cycle was $2,862 for ZARXIO® (11d), $3,582 for NEUPOGEN® (11d) vs. $3926 for NEULASTA® and $3910 for NEULASTA/ONPRO® single-injection. Cost-savings per cycle from ZARXIO® use were $719 vs. NEUPOGEN®, $1,064 vs. NEULASTA®, and $1,047 vs. NEULASTA/ONPRO®. Total savings from ZARXIO® use over all 6 TAC cycles were $4,316 vs. NEUPOGEN®, $6,385 vs. NEULASTA®, and $6,284 vs. NEULASTA/ONPRO®.
CONCLUSIONS: In general, CIN/FN prophylaxis with ZARXIO® for 1-14d generates significant cost savings over NEUPOGEN®, NEULASTA® and NEULASTA/ONPRO generating significant cost-savings. In the case study of the 43 y/o HER-negative breast cancer patient treated with TAC and prescribed 6 cycles of primary prophylaxis with 11d standard or single-administration pegfilgrastim, savings reached as high as $6,385 for the full course of chemotherapy. Given the trial evidence of non-inferiority of pegfilgrastim over filgrastim, the clinical trend for <14d of filgrastim prophylaxis, and payer trends to authorize filgrastim vs. pegfilgrastim prophylaxis, using biosimilar Zarxio® is rational from both a economic perspective; as illustrated also in the breast cancer case study.
Citation Format: McBride A, Campbell K, Bikkina M, MacDonald K, Abraham I, Balu S. Cost-minimization of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar ZARXIO® over NEUPOGEN®, NEULASTA®, and NEULASTA/ONPRO®: Breast cancer case study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-12-07.
Collapse
Affiliation(s)
- A McBride
- Banner University Medical Center, Tucson, AZ; University of Arizona Cancer Center, College of Pharmacy, University of Arizona, Tucson, AZ; Sandoz, Inc., Princeton, NJ; Matrix45, Tucson, AZ; Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ
| | - K Campbell
- Banner University Medical Center, Tucson, AZ; University of Arizona Cancer Center, College of Pharmacy, University of Arizona, Tucson, AZ; Sandoz, Inc., Princeton, NJ; Matrix45, Tucson, AZ; Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ
| | - M Bikkina
- Banner University Medical Center, Tucson, AZ; University of Arizona Cancer Center, College of Pharmacy, University of Arizona, Tucson, AZ; Sandoz, Inc., Princeton, NJ; Matrix45, Tucson, AZ; Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ
| | - K MacDonald
- Banner University Medical Center, Tucson, AZ; University of Arizona Cancer Center, College of Pharmacy, University of Arizona, Tucson, AZ; Sandoz, Inc., Princeton, NJ; Matrix45, Tucson, AZ; Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ
| | - I Abraham
- Banner University Medical Center, Tucson, AZ; University of Arizona Cancer Center, College of Pharmacy, University of Arizona, Tucson, AZ; Sandoz, Inc., Princeton, NJ; Matrix45, Tucson, AZ; Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ
| | - S Balu
- Banner University Medical Center, Tucson, AZ; University of Arizona Cancer Center, College of Pharmacy, University of Arizona, Tucson, AZ; Sandoz, Inc., Princeton, NJ; Matrix45, Tucson, AZ; Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ
| |
Collapse
|
42
|
Campbell K, Li Y, Merchant T, Broniscer A, Tinkle C. Incidence and Kinetics of Neurologic Symptoms During Radiation Therapy for Diffuse Intrinsic Pontine Glioma. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
|
44
|
Ritvo P, Obadia M, Santa Mina D, Alibhai S, Sabiston C, Oh P, Campbell K, McCready D, Auger L, Jones JM. Smartphone-Enabled Health Coaching Intervention (iMOVE) to Promote Long-Term Maintenance of Physical Activity in Breast Cancer Survivors: Protocol for a Feasibility Pilot Randomized Controlled Trial. JMIR Res Protoc 2017; 6:e165. [PMID: 28838886 PMCID: PMC5590009 DOI: 10.2196/resprot.6615] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2016] [Revised: 12/22/2016] [Accepted: 03/25/2017] [Indexed: 12/12/2022] Open
Abstract
Background Although physical activity has been shown to contribute to long-term disease control and health in breast cancer survivors, a majority of breast cancer survivors do not meet physical activity guidelines. Past research has focused on promoting physical activity components for short-term breast cancer survivor benefits, but insufficient attention has been devoted to long-term outcomes and sustained exercise adherence. We are assessing a health coach intervention (iMOVE) that uses mobile technology to increase and sustain physical activity maintenance in initially inactive breast cancer survivors. Objective This pilot randomized controlled trial (RCT) is an initial step in evaluating the iMOVE intervention and will inform development of a full-scale pragmatic RCT. Methods We will enroll 107 physically inactive breast cancer survivors and randomly assign them to intervention or control groups at the University Health Network, a tertiary cancer care center in Toronto, Canada. Participants will be women (age 18 to 74 years) stratified by age (55 years and older/younger than 55 years) and adjuvant hormone therapy (AHT) exposure (AHT vs no AHT) following breast cancer treatment with no metastases or recurrence who report less than 60 minutes of preplanned physical activity per week. Both intervention and control groups receive the 12-week physical activity program with weekly group sessions and an individualized, progressive, home-based exercise program. The intervention group will additionally receive (1) 10 telephone-based health coaching sessions, (2) smartphone with data plan, if needed, (3) supportive health tracking software (Connected Wellness, NexJ Health Inc), and (4) a wearable step-counting device linked to a smartphone program. Results We will be assessing recruitment rates; acceptability reflected in selective, semistructured interviews; and enrollment, retention, and adherence quantitative intervention markers as pilot outcome measures. The primary clinical outcome will be directly measured peak oxygen consumption. Secondary clinical outcomes include health-related quality of life and anthropometric measures. All outcome measures are administered at baseline, after exercise program (month 3), and 6 months after program (month 9). Conclusions This pilot RCT will inform full-scale RCT planning. We will assess pilot procedures and interventions and collect preliminary effect estimates. Trial Registration ClinicalTrials.gov NCT02620735; https://clinicaltrials.gov/ct2/show/NCT02620735 (Archived by WebCite at https://clinicaltrials.gov/ct2/show/NCT02620735)
Collapse
Affiliation(s)
- Paul Ritvo
- School of Kinesiology and Health Science, York University, Toronto, ON, Canada.,Department of Psychology, University of Toronto, Toronto, ON, Canada
| | - Maya Obadia
- Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Daniel Santa Mina
- Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.,Kinesiology and Physical Education, University of Toronto, Toronto, ON, Canada
| | - Shabbir Alibhai
- General Internal Medicine, University Health Network, Toronto, ON, Canada.,Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Catherine Sabiston
- Kinesiology and Physical Education, University of Toronto, Toronto, ON, Canada
| | - Paul Oh
- Cardiovascular Prevention and Rehabilitation Program, Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada.,Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
| | - Kristin Campbell
- Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada
| | - David McCready
- Surgical Oncology, University Health Network, Toronto, ON, Canada.,Division of Surgery, University of Toronto, Toronto, ON, Canada
| | - Leslie Auger
- Kinesiology Program, University of Guelph-Humber, Toronto, ON, Canada
| | - Jennifer Michelle Jones
- Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
45
|
Caballero R, Alfayate S, Utrilla R, Nieto-Marin P, Tinaquero D, Perez-Hernandez M, Matamoros M, Herron T, Campbell K, Lopez-Sendon J, Peinado R, Jalife J, Tamargo J, Delpon E. P5836A mutation in the gene encoding the tbx5 transcription factor is associated with the Brugada Syndrome. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Simon SL, Vigers T, Campbell K, Pyle L, Branscomb R, Nadeau K, Chan CL. 0926 CONTINUOUS GLUCOSE MONITORING, INSULIN RESISTANCE, AND SLEEP IN ADOLESCENTS WITH CYSTIC FIBROSIS. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Geretti E, Espelin C, Adiwijaya B, Coma S, Koncki Z, Sumner P, Dumont N, Garcia G, Bloom T, Janovsky J, Reynolds J, Campbell K, Moyo V, Molnar I, LoRusso P, Krop I, Miller K, Ma C, Munster P, Wickham T. Abstract P4-21-40: In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- E Geretti
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - C Espelin
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - B Adiwijaya
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - S Coma
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - Z Koncki
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - P Sumner
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - N Dumont
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - G Garcia
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - T Bloom
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - J Janovsky
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - J Reynolds
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - K Campbell
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - V Moyo
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - I Molnar
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - P LoRusso
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - I Krop
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - K Miller
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - C Ma
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - P Munster
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - T Wickham
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| |
Collapse
|
48
|
Waclaw RR, Ehrman LA, Merchan-Sala P, Kohli V, Nardini D, Campbell K. Foxo1 is a downstream effector of Isl1 in direct pathway striatal projection neuron development within the embryonic mouse telencephalon. Mol Cell Neurosci 2017; 80:44-51. [PMID: 28213137 DOI: 10.1016/j.mcn.2017.02.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 12/23/2016] [Accepted: 02/13/2017] [Indexed: 12/20/2022] Open
Abstract
Recent studies have shown that the LIM-homeodomain transcription factor Isl1 is required for the survival and differentiation of direct pathway striatonigral neurons during embryonic development. The downstream effectors of Isl1 in these processes are presently unknown. We show here that Foxo1, a transcription factor that has been implicated in cell survival, is expressed in striatal projection neurons (SPNs) that derive from the Isl1 lineage (i.e. direct pathway SPNs). Moreover, Isl1 conditional knockouts (cKOs) show a severe loss of Foxo1 expression at E15.5 with a modest recovery by E18.5. Although Foxo1 is enriched in the direct pathway SPNs at embryonic stages, it is expressed in both direct and indirect pathway SPNs at postnatal time points as evidenced by co-localization with EGFP in both Drd1-EGFP and Drd2-EGFP BAC transgenic mice. Foxo1 was not detected in striatal interneurons as marked by the transcription factor Nkx2.1. Conditional knockout of Foxo1 using Dlx5/6-CIE mice results in reduced expression of the SPN marker Darpp-32, as well as in the direct pathway SPN markers Ebf1 and Zfp521 within the embryonic striatum at E15.5. However, this phenotype improves in the conditional mutants by E18.5. Interestingly, the Foxo family members, Foxo3 and Foxo6, remain expressed at late embryonic stages in the Foxo1 cKOs unlike the Isl1 cKOs where Foxo1/3/6 as well as the Foxo1/3 target Bach2 are all reduced. Taken together, these findings suggest that Foxo-regulated pathways are downstream of Isl1 in the survival and/or differentiation of direct pathway SPNs.
Collapse
Affiliation(s)
- R R Waclaw
- Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
| | - L A Ehrman
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
| | - P Merchan-Sala
- Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
| | - V Kohli
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
| | - D Nardini
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
| | - K Campbell
- Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA; Division of Neurosurgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
| |
Collapse
|
49
|
Burns DS, Fletcher D, Johnston K, Bailey MS, Campbell K. Novel porcine model of cutaneous myiasis: a training tool for healthcare workers. J ROY ARMY MED CORPS 2017; 163:339-341. [PMID: 28193747 DOI: 10.1136/jramc-2016-000737] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 01/09/2017] [Accepted: 01/13/2017] [Indexed: 11/04/2022]
Abstract
Cutaneous myiasis is a well-described problem in travellers to endemic regions including military personnel. Realistic training is important to ensure that healthcare workers have the confidence and expertise to recognise cutaneous myiasis and safely remove larvae if required. A model is described here that is simple, reproducible and realistic, and will allow for training of military healthcare workers in safe surgical removal of larvae when required.
Collapse
Affiliation(s)
- Daniel S Burns
- Department of Infection and Tropical Medicine, Heartlands Hospital, Birmingham, UK.,Army Medical Directorate, Camberley, UK
| | - D Fletcher
- Venning Barracks, DPHC Wales-West Midlands HQ, Telford, Shropshire, UK
| | - K Johnston
- Venning Barracks, DPHC Wales-West Midlands HQ, Telford, Shropshire, UK
| | - M S Bailey
- Department of Infection and Tropical Medicine, Heartlands Hospital, Birmingham, UK.,Department of Military Medicine, Royal Centre for Defence Medicine, Birmingham, UK
| | - K Campbell
- Venning Barracks, DPHC Wales-West Midlands HQ, Telford, Shropshire, UK
| |
Collapse
|
50
|
Campbell K, McKay S, Featherstone C. 132: Role and outcomes of high dose palliative thoracic radiotherapy at the Beatson West of Scotland Cancer Centre. Lung Cancer 2017. [DOI: 10.1016/s0169-5002(17)30182-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|